345 related articles for article (PubMed ID: 31512535)
1. Rituximab biosimilars for lymphoma in Europe.
Jurczak W; Długosz Danecka M; Buske C
Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
[No Abstract] [Full Text] [Related]
2. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
3. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
Rioufol C; Salles G
Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
[TBL] [Abstract][Full Text] [Related]
4. Rituximab biosimilars.
Vital EM; Kay J; Emery P
Expert Opin Biol Ther; 2013 Jul; 13(7):1049-62. PubMed ID: 23600760
[TBL] [Abstract][Full Text] [Related]
5. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
[TBL] [Abstract][Full Text] [Related]
6. The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
Brown JR; Cymbalista F; Sharman J; Jacobs I; Nava-Parada P; Mato A
Oncologist; 2018 Mar; 23(3):288-296. PubMed ID: 29212732
[TBL] [Abstract][Full Text] [Related]
7. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
Buske C; Ogura M; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
Coiffier B
Expert Rev Clin Pharmacol; 2017 Sep; 10(9):923-933. PubMed ID: 28766389
[TBL] [Abstract][Full Text] [Related]
9. Launching biosimilar rituximab: an industry opinion on biosimilar uptake in Europe.
Trollope R; Johnson S; Ireland H
Immunotherapy; 2017 Jun; 9(7):527-529. PubMed ID: 28523951
[TBL] [Abstract][Full Text] [Related]
10. Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA.
Shelbaya A; Kelton JM; Thompson J; Alvir JM; Maculaitis MC; Yang J
Future Oncol; 2021 Oct; 17(30):3941-3950. PubMed ID: 34259584
[TBL] [Abstract][Full Text] [Related]
11. Biosimilar medicines used for cancer therapy in Europe: a review.
Santos SB; Sousa Lobo JM; Silva AC
Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
[TBL] [Abstract][Full Text] [Related]
12. The Economic Impact of Biosimilars in Oncology and Hematology: The Case of Trastuzumab and Rituximab.
Giuliani J; Bonetti A
Anticancer Res; 2019 Jul; 39(7):3971-3973. PubMed ID: 31262930
[TBL] [Abstract][Full Text] [Related]
13. A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.
Choi D; Lee S; Kim S; Yoon S
Clin Drug Investig; 2022 Apr; 42(4):285-300. PubMed ID: 35325438
[TBL] [Abstract][Full Text] [Related]
14. Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany.
Otremba B; Borchardt J; Kuske A; Hollnagel-Schmitz M; Losch FO
Future Oncol; 2020 May; 16(15):1001-1012. PubMed ID: 32286864
[No Abstract] [Full Text] [Related]
15. Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases.
Jurczak W; Cohen S; Illidge TM; Silva AD; Amersdorffer J
Future Oncol; 2019 Dec; 15(36):4223-4234. PubMed ID: 31718287
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
17. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
18. A place for biosimilars in the changing multiple sclerosis treatment landscape.
Greenberg B; Giovannoni G
Mult Scler Relat Disord; 2023 Sep; 77():104841. PubMed ID: 37467536
[TBL] [Abstract][Full Text] [Related]
19. CT-P10 (Truxima™): A Rituximab Biosimilar.
Deeks ED
BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
[TBL] [Abstract][Full Text] [Related]
20. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
Braun J; Kay J
Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
